Estudo RECOVERY – 2 anos.
31 Mar, 2022 | 13:38hThe RECOVERY Trial – two years on – University of Oxford
Conteúdos relacionados:
[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19
RECOVERY trial: Effect of hydroxychloroquine in hospitalized patients with Covid-19
Randomized trial: Lopinavir–ritonavir not beneficial for patients admitted to hospital with COVID-19
Comentário no Twitter
"One trial. Over 47,000 participants. Nearly 200 hospital sites, across six countries. Ten results. Four effective COVID-19 treatments. And behind them all, an army of researchers, doctors, nurses, statisticians and supporting staff."https://t.co/cDlCUkG4cD
— Martin Landray (@MartinLandray) March 28, 2022